Skip to content

Apelin-13

Apelin-13 is an endogenous C-terminal peptide of the 77-residue preproapelin precursor. Its strongest gout-relevant evidence is split across two unjoined branches: one rat/3T3-L1 study connected administered apelin-13 to hyperuricemia and uric-acid-induced adipose oxidative stress, while several other models connected apelin-13 to NF-κB or NLRP3 suppression. No identified study tested apelin-13 against monosodium urate (MSU) crystals, gouty arthritis, or a human gout outcome. The current gout case is therefore a Research Conjecture built from Animal Model and In Vitro premises, not evidence that apelin-13 treats gout.

Exact form and event boundary

The human apelin precursor is UniProt Q9ULZ1. Reactome represents apelin-13 as residues 65–77 in the extracellular region (R-HSA-374315) and groups it with apelin-28, apelin-31, and apelin-36 in an “Apelin peptides” set. That set is an input to the curated event “Apelin receptor binds to apelin” (R-HSA-374337), producing an APLNR:apelin-peptide complex at the plasma membrane. The 1998 isolation study established C-terminal apelin peptides as endogenous APJ/APLNR ligands (In Vitro; PMID 9792798).

This grouping is useful pathway context but is not proof that every apelin form has interchangeable potency, stability, metabolism, or disease effects. In particular, apelin-13 and N-terminally pyroglutamated [Pyr1]apelin-13 must remain distinct reagent identities:

  • The accessible abstract for the 2019 uric-acid study calls its reagent “apelin-13”; PubMed indexes a [Pyr1]apelin-13 substance, but the abstract does not establish the supplied sequence, terminal modification, purity, or manufacturer. Those fields remain unresolved until the full methods or reagent record is inspected.
  • The 2024 human crossover study explicitly administered [Pyr1]apelin-13. Its exposure and physiological results should not be silently transferred to an unspecified apelin-13 reagent.

Gout-relevant evidence

Observed event Evidence What remains unknown
Rats received a 60% fructose diet for 8 weeks and then intraperitoneal apelin-13 for 2 or 12 weeks. The 12-week, but not 2-week, treatment was associated with lower serum urate, lower adipose oxidative-stress and renin–angiotensin-system readouts, and higher APJ expression. Animal Model; PMID 30710622 The accessible abstract does not resolve dose, exact peptide form, food intake/body-weight effects, renal urate transport, urate production, or whether the serum-urate change was direct.
In 3T3-L1 adipocytes exposed to 600 μmol/L uric acid for 48 hours, apelin-13 reduced oxidative-stress and tissue-RAS readouts and increased APJ expression. In Vitro; PMID 30710622 Adipocytes are not gout effector cells; this did not test MSU crystals, macrophages, urate transport, or inflammasome output.
Apelin-13 reduced ROS, NF-κB, and NLRP3-pathway readouts in LPS-injured mouse lung and RAW264.7 cells. Animal Model + In Vitro; PMID 30235451 LPS acute lung injury is not crystal-triggered gout, and the abstract does not isolate priming from inflammasome assembly.
In a rat subarachnoid-hemorrhage model, APJ knockdown or AMPK inhibition abolished apelin-13-associated reductions in TXNIP/NLRP3, cleaved caspase-1, IL-1β, inflammatory and oxidative-stress readouts. Animal Model; PMID 31791369 The trigger, tissue, and resident immune cells differ from gout.
Apelin-13 inhibited NLRP3-mediated pyroptosis in RANKL-driven osteoclastogenesis and titanium-particle mouse calvarial osteolysis through an Nrf2-associated pathway. Animal Model + In Vitro; PMID 38380581 This establishes bone/inflammasome relevance, not an effect on MSU crystals or gouty erosion.
In myocardial-infarction and stressed-macrophage systems, apelin-13 acted through APJ to inhibit NLRP3 assembly, caspase-1 activation, GSDMD cleavage, and IL-1β maturation; pathway inhibitors were used to interrogate the APJ/NLRP3 axis. Animal Model + In Vitro; PMID 42030891 This is direct macrophage mechanism evidence, but the 2026 study used myocardial injury rather than MSU or gout.

The evidence supports three separate statements: apelin-13 can engage APLNR/APJ; apelin-13 altered serum urate and adipose RAS/oxidative readouts in one fructose-fed rat study; and apelin-13 suppressed inflammasome-associated events in several non-gout injury models. It does not yet support a causal edge from APLNR activation to renal or intestinal urate clearance, or from apelin-13 administration to reduced gout flares.

Human exposure and delivery boundary

A randomized, double-blind, placebo-controlled crossover study administered [Pyr1]apelin-13 at 1 or 30 nmol/min to 24 people—12 with chronic kidney disease and 12 matched healthy participants—and measured acute cardiovascular and renal hemodynamics (Clinical Trial; PMID 39402039). Both doses increased renal blood flow and natriuresis relative to placebo; the study did not measure serum urate, urate excretion, MSU inflammation, or gout outcomes. It establishes short-term human exposure to a specified form, not gout efficacy or a uricosuric mechanism.

A separate six-volunteer infusion study recovered intact [Pyr1]apelin-13 and multiple metabolites from human plasma; C-terminally truncated metabolites were prominent (Clinical exposure / analytical study; PMID 31882594). This makes proteolytic stability a real formulation constraint. The direct hyperuricemia study used repeated intraperitoneal administration in rats, while the human studies used infusion. No identified evidence establishes oral delivery, joint exposure, or a durable outpatient formulation for the native peptide.

What would discriminate the gout hypothesis

Before a new experiment, obtain the complete 2019 methods and resolve the administered dose, terminal modification, supplier/purity, group sizes, diet and weight trajectories, kidney-function measures, and any urinary-urate or xanthine-oxidase measurements. If the serum-urate result cannot be separated from altered fructose intake, adiposity, or nonspecific illness, the putative urate-lowering branch should be downgraded.

The direct mechanistic gate is a stage-resolved human macrophage assay using separately identified apelin-13 and [Pyr1]apelin-13:

  1. add peptide before priming versus after priming;
  2. use a defined priming stimulus followed by MSU activation;
  3. include APLNR/APJ blockade and vehicle controls;
  4. measure NF-κB/pro-IL-1β/NLRP3 after priming, then ASC assembly, cleaved caspase-1, GSDMD, mature secreted IL-1β, and viability after MSU.

A reduction confined to pre-priming treatment would support a Signal-1 effect; persistence when peptide is added after priming would justify testing a direct assembly/pyroptosis effect. No change in mature IL-1β at non-cytotoxic exposure would reject the proposed flare-mechanism transfer even if non-gout models remain positive.

Research conjecture — APLNR activation may connect a metabolic urate branch to a macrophage inflammasome branch

Grounded premises: Repeated apelin-13 treatment lowered serum urate and adipose oxidative/RAS readouts in one fructose-fed rat study (Animal Model; PMID 30710622). Reagents reported as apelin-13 suppressed NF-κB/NLRP3-associated events in several injury models, including APJ-dependent inhibition of NLRP3 assembly and IL-1β maturation in stressed macrophages (Animal Model + In Vitro; PMID 30235451, 31791369, 38380581, 42030891).

Novel leap: Apelin-13 or a defined stable form could affect both urate burden and crystal-triggered macrophage inflammation in gout. No direct evidence establishes that combined effect, and the intervening urate-handling mechanism is unknown.

Why it matters: A reproducible two-branch effect would distinguish apelin signaling from peptides that address only inflammatory output.

Discriminating observation: Resolve the 2019 reagent and urate mechanism, then test exact-form, APJ-dependent effects in a stage-resolved human macrophage MSU assay. Failure on either branch rejects the combined hypothesis.

Research-stage analysis. Phase 0 — Research & Design. Not medical advice.